MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Travere Therapeutics Inc

Gesloten

17.95 2.87

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.07

Max

18.05

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.5M

-60M

Verkoop

12M

75M

EPS

-0.47

Winstmarge

-80.586

Werknemers

385

EBITDA

-4.6M

-45M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+95.93% upside

Dividenden

By Dow Jones

Volgende Winsten

5 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-138M

1.7B

Vorige openingsprijs

15.08

Vorige sluitingsprijs

17.95

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Travere Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 feb 2025, 13:58 UTC

Belangrijke Marktbewegers

Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally

Peer Vergelijking

Prijswijziging

Travere Therapeutics Inc Prognose

Koersdoel

By TipRanks

95.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 34.17 USD  95.93%

Hoogste 47 USD

Laagste 22 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Travere Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

13

Buy

1

Hold

0

Sell

Technische score

By Trading Central

17.455 / 20.98Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.